Exact Sciences (EXAS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Exact Sciences Revenue Highlights

Latest Revenue (Y)

$2.76B

Latest Revenue (Q)

$850.74M

Main Segment (Y)

Screening

Main Geography (Y)

UNITED STATES

Exact Sciences Revenue by Period

Exact Sciences Revenue by Year

Date	Revenue	Change
2024-12-31	$2.76B	10.37%
2023-12-31	$2.50B	19.93%
2022-12-31	$2.08B	17.95%
2021-12-31	$1.77B	18.49%
2020-12-31	$1.49B	70.19%
2019-12-31	$876.29M	92.82%
2018-12-31	$454.46M	70.86%
2017-12-31	$265.99M	167.66%
2016-12-31	$99.38M	151.99%
2015-12-31	$39.44M	2093.38%
2014-12-31	$1.80M	-56.61%
2013-12-31	$4.14M	-
2012-12-31	$4.14M	-0.46%
2011-12-31	$4.16M	-22.10%
2010-12-31	$5.34M	12.32%
2009-12-31	$4.76M	-648.79%
2008-12-31	$-867.00K	-129.54%
2007-12-31	$2.94M	-38.21%
2006-12-31	$4.75M	11.76%
2005-12-31	$4.25M	-13.88%
2004-12-31	$4.93M	70.11%
2003-12-31	$2.90M	223.41%
2002-12-31	$897.00K	1663.32%
2001-12-31	$50.87K	5086900.00%
2000-12-31	$1.00	100.00%
1999-12-31	-	100.00%
1998-12-31	-	-

Exact Sciences generated $2.76B in revenue during NA 2024, up 10.37% compared to the previous quarter, and up 314.83% compared to the same period a year ago.

Exact Sciences Revenue by Quarter

Date	Revenue	Change
2025-09-30	$850.74M	4.89%
2025-06-30	$811.09M	14.76%
2025-03-31	$706.78M	-0.93%
2024-12-31	$713.42M	0.67%
2024-09-30	$708.65M	1.34%
2024-06-30	$699.26M	9.68%
2024-03-31	$637.52M	-1.45%
2023-12-31	$646.88M	2.95%
2023-09-30	$628.34M	1.00%
2023-06-30	$622.09M	3.26%
2023-03-31	$602.45M	8.94%
2022-12-31	$553.00M	5.72%
2022-09-30	$523.07M	0.27%
2022-06-30	$521.64M	7.21%
2022-03-31	$486.57M	2.69%
2021-12-31	$473.81M	3.82%
2021-09-30	$456.38M	4.96%
2021-06-30	$434.82M	8.14%
2021-03-31	$402.08M	-13.78%
2020-12-31	$466.34M	14.20%
2020-09-30	$408.36M	51.88%
2020-06-30	$268.87M	-22.70%
2020-03-31	$347.82M	17.68%
2019-12-31	$295.57M	35.09%
2019-09-30	$218.81M	9.47%
2019-06-30	$199.87M	23.34%
2019-03-31	$162.04M	13.33%
2018-12-31	$142.98M	20.87%
2018-09-30	$118.29M	14.96%
2018-06-30	$102.89M	13.95%
2018-03-31	$90.30M	3.31%
2017-12-31	$87.41M	20.44%
2017-09-30	$72.57M	25.90%
2017-06-30	$57.65M	19.19%
2017-03-31	$48.36M	37.24%
2016-12-31	$35.24M	25.35%
2016-09-30	$28.11M	32.71%
2016-06-30	$21.18M	42.80%
2016-03-31	$14.84M	17.44%
2015-09-30	$12.63M	55.59%
2015-06-30	$8.12M	90.32%
2015-03-31	$4.27M	183.64%
2014-12-31	$1.50M	100.00%
2014-09-30	-	100.00%
2014-06-30	-	-100.00%
2014-03-31	$294.00K	-71.62%
2013-12-31	$1.04M	-
2013-09-30	$1.04M	-
2013-06-30	$1.04M	-
2013-03-31	$1.04M	-
2012-12-31	$1.04M	-
2012-09-30	$1.04M	-
2012-06-30	$1.04M	-
2012-03-31	$1.04M	-0.58%
2011-12-31	$1.04M	0.29%
2011-09-30	$1.04M	-0.29%
2011-06-30	$1.04M	0.19%
2011-03-31	$1.04M	-24.36%
2010-12-31	$1.38M	1.40%
2010-09-30	$1.36M	3.20%
2010-06-30	$1.31M	1.15%
2010-03-31	$1.30M	4.42%
2009-12-31	$1.24M	-0.96%
2009-09-30	$1.26M	-0.16%
2009-06-30	$1.26M	25.80%
2009-03-31	$1.00M	-152.74%
2008-12-31	$-1.90M	-662.61%
2008-09-30	$337.00K	100.00%
2008-06-30	-	-100.00%
2008-03-31	$51.00K	-90.50%
2007-12-31	$537.00K	-

Exact Sciences generated $850.74M in revenue during Q3 2025, up 4.89% compared to the previous quarter, and up 121.66% compared to the same period a year ago.

Exact Sciences Revenue Breakdown

Exact Sciences Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
Precision Oncology	$655.00M	-	-	-	-
COVID-19 Testing	-	$58.09M	$143.10M	$235.83M	-
Screening	$2.10B	-	-	-	-
Product	-	$545.46M	$438.65M	$365.47M	$404.33M
Product and Service, Other	-	$136.01M	$53.72M	$39.92M	$37.78M
International Sales	-	$117.74M	$109.91M	$77.48M	$11.44M
Service	-	$743.24M	$569.94M	$409.67M	$368.01M

Exact Sciences's latest annual revenue breakdown by segment (product or service), as of Dec 24: Screening (76.26%), and Precision Oncology (23.74%).

Quarterly Revenue by Product

Product/Service	Sep 25	Jun 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Screening	$666.24M	$628.48M	$552.56M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Precision Oncology	$184.50M	$182.60M	$160.86M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
COVID-19 Testing	-	-	-	-	-	-	$5.96M	-	$2.13M	$3.82M	$6.04M	$10.87M	$13.75M	$27.43M	$47.10M	$30.59M	$33.07M	$32.34M	$99.09M	$102.16M
Service	-	-	-	-	-	-	-	-	$245.75M	$233.03M	$211.45M	$188.92M	$181.19M	$161.68M	$150.68M	$151.25M	$140.15M	$127.87M	$129.22M	$106.00M
Product	-	-	-	-	-	-	-	-	$176.02M	$171.73M	$156.09M	$140.37M	$135.25M	$113.75M	$109.61M	$116.09M	$111.39M	$101.56M	$108.88M	$98.85M
Product and Service, Other	-	-	-	-	-	-	-	-	$41.02M	$38.43M	$35.99M	$31.47M	$37.46M	$31.09M	$17.38M	$13.04M	$12.40M	$10.89M	$11.56M	$9.77M
International Sales	-	-	-	-	-	-	-	-	$35.59M	$37.27M	$28.20M	$31.53M	$28.34M	$29.44M	$29.78M	$27.23M	$26.85M	$26.06M	$21.26M	$16.24M

Exact Sciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Screening (78.31%), and Precision Oncology (21.69%).

Exact Sciences Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
Non-US	$189.09M	$117.74M	$109.91M	$77.48M	$11.44M
UNITED STATES	$2.57B	$1.97B	$1.66B	$1.41B	$864.85M

Exact Sciences's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (93.15%), and Non-US (6.85%).

Quarterly Revenue by Country

Country	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
UNITED STATES	$791.96M	$755.83M	$655.20M	$665.02M	$659.22M	$652.54M	$592.99M	$2.35B	$589.74M	$586.51M	$565.18M	$491.54M	$493.30M	$457.13M	$429.15M	$407.97M	$376.02M	$445.08M	$392.12M	$249.85M
Non-US	$58.78M	$55.26M	$51.59M	$48.40M	$49.43M	$46.72M	$44.53M	$153.28M	$38.60M	$35.59M	$37.27M	$31.53M	$28.34M	$29.44M	$27.23M	$26.85M	$26.06M	$21.26M	$16.24M	$19.02M

Exact Sciences's latest quarterly revenue breakdown by geography, as of Sep 25: UNITED STATES (93.09%), and Non-US (6.91%).

Exact Sciences Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
VTRS	Viatris	$14.74B	$3.76B
ICLR	ICON Public	$8.12B	$2.09B
EXAS	Exact Sciences	$2.76B	$850.74M
RVTY	Revvity	$2.76B	$698.95M
QGEN	Qiagen	$1.97B	$458.80M
GH	Guardant Health	$739.02M	$265.20M
DOCS	Doximity	$570.40M	$145.91M
BBIO	BridgeBio Pharma	$221.90M	$108.11M
ROIV	Roivant Sciences	$124.80M	$1.57M
RVMD	Revolution Medicines	-	-
SMMT	Summit Therapeutics	-	-

EXAS Revenue FAQ

What is Exact Sciences’s yearly revenue?

Exact Sciences's yearly revenue for 2024 was $2.76B, representing an increase of 10.37% compared to 2023. The company's yearly revenue for 2023 was $2.5B, representing an increase of 19.93% compared to 2022. EXAS's yearly revenue for 2022 was $2.08B, representing an increase of 17.95% compared to 2021.

What is Exact Sciences’s quarterly revenue?

Exact Sciences's quarterly revenue for Q3 2025 was $850.74M, a 4.89% increase from the previous quarter (Q2 2025), and a 20.05% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $811.08M, a 14.76% increase from the previous quarter (Q1 2025), and a 15.99% increase year-over-year (Q2 2024). EXAS's quarterly revenue for Q1 2025 was $706.78M, a -0.93% decrease from the previous quarter (Q4 2024), and a 10.86% increase year-over-year (Q1 2024).

What is Exact Sciences’s revenue growth rate?

Exact Sciences's revenue growth rate for the last 3 years (2022-2024) was 32.37%, and for the last 5 years (2020-2024) was 84.99%.

What are Exact Sciences’s revenue streams?

Exact Sciences's revenue streams in c 24 are Precision Oncology, and Screening. Precision Oncology generated $655M in revenue, accounting 23.74% of the company's total revenue Screening generated $2.1B in revenue, accounting 76.26% of the company's total revenue

What is Exact Sciences’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Exact Sciences was Screening. This segment made a revenue of $2.1B, representing 76.26% of the company's total revenue.